Low-dose steroids for immunotherapy-related liver inflammation
Part of Cancer clinical trials.
This trial tests whether using low-dose steroids can safely manage liver inflammation caused by immunotherapy. It may help patients who have moderate liver problems from their cancer treatment but haven't yet started high-dose steroids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You are currently taking an immunotherapy drug (such as PD-1, PD-L1, CTLA-4, or LAG-3 inhibitor).
- You have developed moderate to severe liver inflammation (grade 2 or 3) from your immunotherapy.
- You have not already been treated for this liver inflammation with high-dose steroids.
- You do not have another serious liver disease (like active hepatitis B or C, cirrhosis, or autoimmune hepatitis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, mycophenolate mofetil and prednisone, to treat moderate to severe liver inflammation caused by immunotherapy. The goal is to see if this treatment can help control the inflammation without needing long-term high-dose steroids.
This trial studies a way to treat inflammation of the liver (hepatitis) caused by immune cancer medicines (anti-PD-1/PD-L1, sometimes with anti-CTLA-4) without relying on high-dose steroids. It may help reduce steroid side effects while keeping liver inflammation under control.
This study follows people who develop liver inflammation (hepatitis) after starting immunotherapy for cancer. It helps doctors understand how often this happens and how to manage it.
This trial tests whether adding a low dose of radiation to the liver can make standard immunotherapy work better for people with non-small cell lung cancer or melanoma that has spread to the liver.
This trial tests whether steroids (glucocorticoids) can help people with acute liver injury caused by a drug, especially when bilirubin levels are high. It aims to see if steroids can reduce liver damage and improve recovery.
This trial tests whether prednisone (an anti-inflammatory steroid) can help protect the liver in people with hepatocellular carcinoma who are getting stereotactic body radiation therapy. It may reduce liver stress from radiation and help you tolerate treatment safely.
Hear when a new Immune-Mediated Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.